Minocycline 是一种口服有效且能透过血脑屏障的半合成四环素类抗生素,作为缺氧诱导因子 (HIF-1α) 抑制剂,具有抗癌 (anti-cancer)、抗炎 (anti-inflammatory) 和谷氨酸 (glutamate) 拮抗作用,可降低谷氨酸神经传递,显示出神经保护特性和抗抑郁作用,并通过与细菌核糖体 30S 亚基结合抑制细菌蛋白合成,从而产生抑菌 (bacteriostatic) 作用。
产品编号: MS-Q89694 纯度: 98.59% CAS No.: 10118-90-8 分子式: C23H27N3O7 分子量: 457.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Minocycline 是一种口服有效且能透过血脑屏障的半合成四环素类抗生素,作为缺氧诱导因子 (HIF-1α) 抑制剂,具有抗癌 (anti-cancer)、抗炎 (anti-inflammatory) 和谷氨酸 (glutamate) 拮抗作用,可降低谷氨酸神经传递,显示出神经保护特性和抗抑郁作用,并通过与细菌核糖体 30S 亚基结合抑制细菌蛋白合成,从而产生抑菌 (bacteriostatic) 作用。

生物实验数据

生物活性 Minocycline is an orally effective, blood-brain barrier-penetrating semisynthetic tetracycline antibiotic that acts as a hypoxia-inducible factor (HIF-1α) inhibitor, exhibits anti-cancer, anti-inflammatory, and glutamate antagonistic effects, reduces glutamatergic neurotransmission, demonstrates neuroprotective and antidepressant properties, and produces a bacteriostatic effect by binding to the bacterial ribosomal 30S subunit to inhibit bacterial protein synthesis.
IC50 & Target

L-type calcium channel

 

体外研究
(In Vitro)

Minocycline (0-100 μM,24-72 小时) 可抑制卵巢癌细胞系 (OVCAR-3、SKOV-3 和 A2780) 的增殖和克隆形成活性。
Minocycline (0-100 μM,24-48 小时) 通过抑制细胞周期蛋白和抑制 DNA 掺入来阻滞细胞周期。
Minocycline (0-100 μM,72 小时) 可诱导卵巢癌细胞系细胞凋亡。
Minocycline 具有直接的神经元保护作用,这种保护模式可能是与线粒体完整性和细胞色素c的维持相关,进而抑制胱天蛋白酶依赖性和非胱天蛋白酶依赖性的细胞死亡。
Minocycline 可抑制缺氧诱导因子 (HIF)-1α,同时上调 p53 蛋白水平并失活 AKT/mTOR/p70S6K/4E-BP1 通路。

Cell Proliferation Assay

Cell Line: Human ovarian cancer cell lines (OVCAR-3, SKOV-3 and A2780) and primary cells (HEK-293, HMEC, HUVEC, ATCC)
Concentration: 0, 1, 10, 50 and 100 μM
Incubation Time: 24, 48 or 72 h
Result: Inhibited proliferation of OVCAR-3, SKOV-3 and A2780 cells in a concentration-dependent manner, with IC50 values of 62.0, 56.1 and 59.5 μM, respectively. Had no effect on the viability of HEK-293 or HUVEC.

Cell Cycle Analysis

Cell Line: OVCAR-3, SKOV-3 and A2780 cells
Concentration: 0, 10, 50 and 100 μM
Incubation Time: 24 or 48 h
Result: Arrested cells in the G0-G1 phase in a concentration and time-dependent manner. Declined percentage of cells in the S and G2-M phases in excess of 80% each at 100 μM.

Western Blot Analysis

Cell Line: OVCAR-3, SKOV-3 and A2780 cells
Concentration: 0, 10, 50 and 100 μM
Incubation Time: 72 h
Result: Expressed lower levels of cyclins A, B and E. Increased caspase-3 levels by more than 3.0 fold in the 100 μM. Minocycline-activated caspase-3 in turn led to cleavage of PARP-1. Increased the degradation product p89 of PARP-1 by caspase-3.
体内研究
(In Vivo)

Minocycline (0-30 mg/kg,口服,每日一次,持续 4 周) 可抑制雌性裸鼠体内 OVCAR-3 肿瘤的生长。
Minocycline (腹腔注射) 在脑缺血动物模型中,以大剂量腹腔注射给药时,是一种有效的神经保护剂。
Minocycline (0-40 mg/kg,腹腔注射,一次) 可显著减弱METH诱导的小鼠运动亢进和行为敏化的发展。
Minocycline (3 和 10 mg/kg,静脉注射,一次) 可有效减少暂时性中梗死面积。脑动脉闭塞模型 (TMCAO)。
Minocycline 可减轻大鼠缺血诱发的室性心律失常。这种作用可能与 PI3K/Akt 信号通路、线粒体 KATP 通道和 L 型 Ca2+ 通道的激活有关。

Animal Model: Female nude mice (6 weeks old, 9 per group, OVCAR-3 cells were injected s.c. into the left flank of each mouse)
Dosage: 10 or 30 mg/kg
Administration: Administered orally in the drinking water, initiated on day 8 of cell inoculation, daily for 4 weeks
Result: Suppressed OVCAR-3 tumor growth in these female nude mice, and reduced microvessel density.
Animal Model: Male Balb/cAnNCrICrIj mice (8 weeks old, 23-30 g, methamphetamine (METH, 3 mg/kg) was injected subcutaneously (s.c.) in a volume of 10 ml/kg)
Dosage: 0, 10, 20, or 40 mg/kg
Administration: IP, once, 30 min before the administration of METH
Result: Significantly attenuated METH-induced hyperlocomotion and the development of behavioral sensitization in mice at 40 mg/kg. Did not exert any effect on the induction of METH-induced hyperthermia in mice. Significantly attenuated the reduction of DA and DOPAC in the striatum. Significantly attenuated the reduction of DAT-immunoreactivity in the mouse striatum. Significantly attenuated the increase in MAC1-immunoreactivity in the striatum after the administration of METH.
Animal Model: Male Sprague-Dawley rats (270-330 g, TMCAO model)
Dosage: 3 mg/kg and 10 mg/kg
Administration: IV, once, 4, 5, or 6 hours post TMCAO
Result: Reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56% at doses of 3 mg/kg; significantly reduced infarct size at 5 hours by 40% at doses of 10 mg/kg and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction.
Animal Model: Male Sprague-Dawley rats (270-330 g)
Dosage: 3, 10, or 20 mg/kg
Administration: IV, once
Result: Peak concentrations of serum levels of minocycline averaged 3.6, 13.0 and 28.8 mg/L with 3, 10 and 20 mg/kg doses respectively. The serum levels of minocycline at a 3 mg/kg dose (3.6 mg/L) were similar to that reported in humans after a standard 200 mg dose. Did not significantly affect hemodynamic and physiological variables.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 457.48
分子式 C23H27N3O7
CAS No. 10118-90-8

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 2 mg/mL (4.37 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (54.65 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1859 mL10.9294 mL21.8589 mL54.6472 mL
5 mM0.4372 mL2.1859 mL4.3718 mL10.9294 mL
10 mM0.2186 mL1.0929 mL2.1859 mL5.4647 mL
15 mM0.1457 mL0.7286 mL1.4573 mL3.6431 mL
20 mM0.1093 mL0.5465 mL1.0929 mL2.7324 mL
25 mM0.0874 mL0.4372 mL0.8744 mL2.1859 mL
30 mM0.0729 mL0.3643 mL0.7286 mL1.8216 mL
40 mM0.0546 mL0.2732 mL0.5465 mL1.3662 mL
50 mM0.0437 mL0.2186 mL0.4372 mL1.0929 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础